

# Pharmacological mTOR targeting enhances the antineoplastic effects of selective PI3K $\alpha$ inhibition in medulloblastoma

Frank Eckerdt<sup>1,2,§,\*</sup>, Jessica Clymer<sup>1,3,§,¶</sup>, Jonathan B. Bell<sup>1</sup>, Elspeth M. Beauchamp<sup>1,4,5</sup>, Gavin T. Blyth<sup>1</sup>, Stewart Goldman<sup>1,3</sup>, and Leonidas C. Platanias<sup>1,4,5</sup>

<sup>1</sup>Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA

<sup>2</sup>Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

<sup>3</sup>Division of Hematology/Oncology/Neuro Oncology/Stem Cell Transplantation, Department of Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA

<sup>4</sup>Division of Hematology/Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

<sup>5</sup>Medicine Service, Jesse Brown VA Medical Center, Chicago, IL, USA

<sup>§</sup>Both authors contributed equally

<sup>¶</sup>Current address: Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA

\*Correspondence to: Frank Eckerdt, Robert H. Lurie Comprehensive Cancer Center, 303 East Superior Street, Lurie 3-220, Chicago, IL 60611, Tel. 312-503-0292; Email: [frank.eckerdt@northwestern.edu](mailto:frank.eckerdt@northwestern.edu)

Supplemental Table 1

<b>ANTIBODY</b>	<b>SOURCE</b>	<b>IDENTIFIER</b>
p70S6K (49D7)	Cell Signaling Technology	Cat#:2708 RRID:AB_390722
p-p70S6K T389	Cell Signaling Technology	Cat#:9205 RRID:AB_330944
Lamin A/C	Cell Signaling Technology	Cat#:2032 RRID:AB_2136278
Beta-tubulin (D3U1W)	Cell Signaling Technology	Cat#:86298 RRID:AB_2715541
Alpha-tubulin (B-7)	Santa Cruz Biotechnology	Cat#:sc-5286 RRID:AB_628411
HSP-90 (H-114)	Santa Cruz Biotechnology	Cat#:sc-7947 RRID:AB_2121235
PI3 Kinase p110alpha (c73F8)	Cell Signaling Technology	Cat# 4249 RRID: AB_2165248
GAPDH	Millipore	Cat# MAB374, RRID:AB_2107445
Pan AKT (40D4)	Cell Signaling Technology	Cat# 2920 RRID:AB_1147620
p-AKT S473 (D9E)	Cell Signaling Technology	Cat# 4060 RRID:AB_2315049
4EBP1	Cell Signaling Technology	Cat# 9452 RRID:AB_331692
p-4EBP1 T37/46	Cell Signaling Technology	Cat# 9459 RRID: AB_330985
GLI1	Cell Signaling Technology	Cat# 3538 RRID:AB_1903989
HDAC1 (10E2)	Cell Signaling Technology	Cat# 5356 RRID:AB_10612242
Rabbit IgG HRP Linked Whole Ab	GE Healthcare	NA934-1ML RRID:AB_772206
Goat Anti-Mouse IgG (H + L)-HRP Conjugate	Biorad	Cat#:1706516 RRID:AB_11125547

Supp Table 1: List of antibodies used in this study, their manufacturers, catalog numbers and Research Resource Identifier (RRID) numbers.

Figure 1A and B full blots (films)











Figure 1A and B full blots (films)



# Figure 3A full blots (Biorad Chemidoc)


11.3 sec exposure



GLI1

LaminA/C  
and tubulin

289.7 sec exposure




GLI1

LaminA/C  
and tubulin

# Figure 3B full blots (Biorad Chemidoc)


5.1 sec exposure



GLI1

LaminA/C  
and tubulin

120.0 sec exposure




GLI1

LaminA/C  
and tubulin

# Figure 3C full blots (Biorad Chemidoc)


120.0 sec exposure



GLI1

tubulin

120.0 sec exposure



HDAC1

Figure 4G and H full blots (films).

Other p110 isoform siRNAs were cropped out because a similar experiment has been published in our previous study (ref. 26).

